小肠移植缺血再灌注损伤的防治研究进展  

Research progress on prevention and treatment of ischemia-reperfusion injury in intestinal transplantation

作　　者：徐敏[1] 杨涛[2] 孟珂伟 王翀[2] Xu Min;Yang Tao;Meng Kewei;Wang Chong(Tianjin Medical University First Central Clinical College, Tianjin 300192, China;General Surgery Department, Tianjin First Central Hospital, Tianjin 300192, China)

机构地区：[1]天津医科大学一中心临床学院,300192 [2]天津市第一中心医院普通外科,300192

出　　处：《中国医师杂志》2019年第5期791-794,共4页Journal of Chinese Physician

基　　金：国家国际科技合作专项项目(2015DFG31805)~~

摘　　要：小肠移植是治疗小肠功能衰竭和肠外营养失败的唯一选择。尽管免疫抑制治疗取得的进步和外科技术的改进改善了小肠移植的预后,但与其他实体器官移植相比仍不令人满意,主要原因是小肠黏膜容易因缺血导致损伤。缺血再灌注损伤的基本病理生理过程是缺血/再灌注诱导活性氧(ROS)产生、炎症反应和细胞凋亡,从而导致组织损伤。近年来,小肠移植缺血再灌注损伤的病理生理研究取得一些新的进展,为小肠移植缺血再灌注损伤的防治提供更多可能性,尽管大多为动物实验结果,但对临床应用有重要参考价值。Intestinal transplantation is the only treatment option for irreversible intestinal failure and parenteral nutrition failure. Although the progress of immunosuppressive therapy and the improvement of surgical techniques have improved the prognosis of intestinal transplantation, it is still unsatisfactory compared with other solid organ transplantation, mainly due to the fact that the intestinal mucosa is susceptible to damage due to ischemia. The basic pathophysiological process of ischemia-reperfusion injury(IRI) is that ischemia/reperfusion induces the production of reactive oxygen species (ROS), inflammation and cell apoptosis, leading to tissue damage. In recent years, the pathophysiology of ischemia-reperfusion injury in intestinal transplantation has made some new progress, providing more possibilities for the prevention and treatment of intestinal transplantation IRI.Although most of them are animal experimental results, they have important reference value for clinical application.

关 键 词：小肠 器官移植 再灌注损伤 缺血预处理 综述 

分 类 号：R656.7[医药卫生—外科学]